Management of Pain in Stage 4 Cancer Patients

Assessment and Evaluation

The European Society for Medical Oncology recommends that all cancer patients should be evaluated for pain at every clinical visit using standardized self-reporting tools such as visual analog scales (VAS), numerical rating scales (NRS), or verbal rating scales (VRS) 1, 3
Pain assessment should include characterization of type, location, intensity, duration, and temporal patterns, as well as relieving and exacerbating factors, according to the European Society for Medical Oncology 3, 5
For patients with cognitive impairment, the European Society for Medical Oncology recommends observation of pain-related behaviors and discomfort, such as facial expressions, body movements, and vocalizations 3, 5

The American Society of Clinical Oncology recommends using non-opioid analgesics such as acetaminophen/paracetamol (maximum 4000 mg/day) or NSAIDs for mild pain, with gastroprotection to prevent GI toxicity 1, 2
For moderate pain, the American Society of Clinical Oncology suggests adding weak opioids such as codeine, dihydrocodeine, or tramadol to non-opioid analgesics, or using low doses of strong opioids such as morphine or oxycodone 1, 2
The American Society of Clinical Oncology recommends using strong opioids such as morphine (preferred), hydromorphone, oxycodone, or fentanyl for severe pain, with oral administration preferred when possible 2, 4

The European Society for Medical Oncology recommends providing around-the-clock dosing for persistent pain rather than "as needed" administration, with "breakthrough" doses (typically 10-15% of total daily dose) for transient pain exacerbations 3, 5, 4
The American Society of Clinical Oncology suggests titrating doses rapidly to achieve effective pain control, and adjusting the baseline opioid regimen if more than four breakthrough doses are needed daily 2, 4, 6

The American Society of Clinical Oncology recommends anticipating and proactively managing common side effects, including constipation, nausea/vomiting, and central nervous system toxicity, with prophylactic laxatives, antiemetics, and dose reduction or opioid rotation as needed 2

The American Society of Clinical Oncology suggests considering adjuvant analgesics such as anticonvulsants (gabapentin, pregabalin), antidepressants (tricyclics, SNRIs), and corticosteroids for neuropathic pain, and bone-modifying agents (bisphosphonates, denosumab) for bone pain 2, 4

The National Comprehensive Cancer Network recommends considering interventional strategies when pain is inadequately controlled despite optimal pharmacologic therapy, or when opioid side effects are intolerable, with options including regional infusion of analgesics, nerve blocks, and vertebral augmentation 7, 4

The American Society of Clinical Oncology recommends considering radiation therapy for localized bone pain, surgical stabilization for impending fractures, and psychological interventions to address anxiety and depression, as well as patient education about pain management options 4, 6, 3, 7

The National Comprehensive Cancer Network recommends obtaining regular pain ratings and documenting them in medical records, adjusting treatment based on changes in pain intensity, side effects, and disease progression, and providing patients with written follow-up plans and instructions on medication adherence 4, 7

The European Society for Medical Oncology notes that over 80% of patients with advanced metastatic cancer experience pain, primarily from direct tumor infiltration, and approximately 20% of pain in cancer patients may be attributed to effects of surgery, radiotherapy, or chemotherapy 1, 2